Commodore Capital LP's 9.8% Ownership in Alto Neuroscience, Inc.

Commodore Capital LP, along with Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, filed a Schedule 13G on October 27, 2025, disclosing a 9.8% ownership in Alto Neuroscience, Inc. The filing indicates that Commodore Capital LP beneficially owns 3,190,267 shares of Common Stock, including shares acquired through the exercise of a pre-funded warrant. The ownership percentage is based on 30,908,892 shares of Common Stock outstanding as of October 20, 2025, plus 1,536,354 shares that may be acquired upon the exercise of the pre-funded warrant. The filing certifies that the securities were not acquired for the purpose of influencing the control of the issuer.